IL182459A0 - Compounds for nonsense suppression, and methods for their use - Google Patents
Compounds for nonsense suppression, and methods for their useInfo
- Publication number
- IL182459A0 IL182459A0 IL182459A IL18245907A IL182459A0 IL 182459 A0 IL182459 A0 IL 182459A0 IL 182459 A IL182459 A IL 182459A IL 18245907 A IL18245907 A IL 18245907A IL 182459 A0 IL182459 A0 IL 182459A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- nonsense suppression
- nonsense
- suppression
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/24—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00Â -Â C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
- C07F9/65306—Five-membered rings containing two nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61763304P | 2004-10-13 | 2004-10-13 | |
| US61763404P | 2004-10-13 | 2004-10-13 | |
| US61765504P | 2004-10-13 | 2004-10-13 | |
| US61765304P | 2004-10-13 | 2004-10-13 | |
| US61767004P | 2004-10-13 | 2004-10-13 | |
| US62417004P | 2004-11-03 | 2004-11-03 | |
| PCT/US2005/036673 WO2006044456A1 (en) | 2004-10-13 | 2005-10-13 | Compounds for nonsense suppression, and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL182459A0 true IL182459A0 (en) | 2007-07-24 |
Family
ID=35517967
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL182459A IL182459A0 (en) | 2004-10-13 | 2007-04-11 | Compounds for nonsense suppression, and methods for their use |
| IL182464A IL182464A0 (en) | 2004-10-13 | 2007-04-11 | Compounds for nonsense suppression, and methods for their use |
| IL182461A IL182461A0 (en) | 2004-10-13 | 2007-04-11 | Compounds for nonsense suppression, and methods for their use |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL182464A IL182464A0 (en) | 2004-10-13 | 2007-04-11 | Compounds for nonsense suppression, and methods for their use |
| IL182461A IL182461A0 (en) | 2004-10-13 | 2007-04-11 | Compounds for nonsense suppression, and methods for their use |
Country Status (11)
| Country | Link |
|---|---|
| US (10) | US9051342B2 (cg-RX-API-DMAC10.html) |
| EP (13) | EP2363129A1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2008515992A (cg-RX-API-DMAC10.html) |
| KR (3) | KR20070065429A (cg-RX-API-DMAC10.html) |
| AU (3) | AU2005295730A1 (cg-RX-API-DMAC10.html) |
| BR (2) | BRPI0515995A (cg-RX-API-DMAC10.html) |
| CA (5) | CA2582885A1 (cg-RX-API-DMAC10.html) |
| IL (3) | IL182459A0 (cg-RX-API-DMAC10.html) |
| MX (3) | MX2007004479A (cg-RX-API-DMAC10.html) |
| SG (2) | SG156640A1 (cg-RX-API-DMAC10.html) |
| WO (5) | WO2006044502A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003252136A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| EP4101846B1 (en) | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| JP2008515992A (ja) * | 2004-10-13 | 2008-05-15 | ăăźăăŁăźăˇăź ăťăŠăăĽăźăăŁăŻăšďźă¤ăłăłăźăăŹăźăăă | ä˝ç´°čĺ¤ç°ăŤčľˇĺ ăăçžćŁăŽéťć˘ďźć˛ťçç¨ĺťčŹă製é ăăăăăŽčŚĺŽĺĺçŠăŽä˝żç¨ |
| EP1940801A2 (en) * | 2005-10-14 | 2008-07-09 | NeuroSearch A/S | Imidazole derivatives and their use for modulating the gaba-a receptor complex |
| WO2007047706A2 (en) * | 2005-10-17 | 2007-04-26 | Children's Hospital | Methods and compositions for regulating gene expression |
| BRPI0707719A2 (pt) | 2006-02-10 | 2011-05-10 | Summit Corp Plc | uso de um composto ou de um sal farmaceuticamente aceitĂvel do mesmo |
| EP2387995A1 (en) | 2006-03-30 | 2011-11-23 | PTC Therapeutics, Inc. | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
| JP5420395B2 (ja) | 2006-04-07 | 2014-02-19 | ăăźăăăŻăš ăăĄăźăăˇăĽăźăăŁăŤăŤăş ă¤ăłăłăźăăŹă¤ăăă | ď˝ď˝çľĺăŤăťăă蟸éä˝ăŽčŞżçŻĺ¤ |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| UA99600C2 (en) * | 2006-09-25 | 2012-09-10 | ĐиТиХи ТĐĐ ĐĐЏЎТĐĐĐĄ, ĐĐĐ. | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| KR100858357B1 (ko) * | 2006-10-02 | 2008-09-11 | (죟) ëě§íë°ě´ě¤í | 벤쥰í¨ëęł ě ë체 ííŠëŹźě ě í¨ěąëśěźëĄ í¨ě íëě¸ě§ę¸°ëĽ ěĽě ě ěë°Š ë° ěšëŁěŠ ěĄ°ěąëŹź |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| WO2008157407A2 (en) * | 2007-06-13 | 2008-12-24 | University Of Virginia Patent Foundation | Thiadiazole, oxadiazole and triazole derivatives for treating leukemia |
| AU2008285289A1 (en) | 2007-08-03 | 2009-02-12 | Biomarin Iga Limited | Drug combinations for the treatment of Duchenne muscular dystrophy |
| WO2009049159A1 (en) | 2007-10-10 | 2009-04-16 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
| CN102743385B (zh) | 2007-11-16 | 2014-09-17 | ć˛ćł°ĺ ćŻčŻçŠčĄäť˝ćéĺ Źĺ¸ | Atpçťĺç轏čżčç˝çĺźĺšĺč°čĺ |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropĂĄnkarboxamido)-3-metilpiridin-2-il)-benzoesav szilĂĄrd formĂĄi |
| NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| JP5369854B2 (ja) | 2008-04-21 | 2013-12-18 | ä˝ĺĺĺŚć Şĺźäźç¤ž | ć厳çŻčśłĺçŠé˛é¤çľćçŠăăăłç¸Žĺč¤ç´ ç°ĺĺçŠ |
| US8530483B2 (en) | 2008-05-30 | 2013-09-10 | Merck Sharp & Dohme Corp. | Substituted azabenzoxazoles |
| TW201000099A (en) | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| WO2010008831A2 (en) * | 2008-06-24 | 2010-01-21 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| SG174125A1 (en) * | 2009-04-02 | 2011-10-28 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| US9126938B2 (en) | 2009-08-17 | 2015-09-08 | The Brigham And Women's Hospital, Inc. | Phosphatidylcholine transfer protein inhibitors |
| CN102573478B (zh) | 2009-10-12 | 2015-12-16 | ćĺ°ĺä˝çŠç§ĺŚčĄäť˝ĺ Źĺ¸ | ä˝ä¸şćčŤĺç1-(ĺĄĺś-3-ĺş)-ĺĄĺĺ1-(ĺ§ĺś-5-ĺş)-ĺĄĺ |
| US20130040983A1 (en) * | 2010-01-08 | 2013-02-14 | Jean-Michel Vernier | Raf kinase inhibitors |
| EP2563778B1 (en) | 2010-03-25 | 2016-08-24 | Vertex Pharmaceuticals Incorporated | Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacĂŠuticas de ĂĄcido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administraciĂłn de las mismas |
| TWI549950B (zh) | 2010-04-07 | 2016-09-21 | çśćł°ĺ ćŻčŁ˝čĽĺ Źĺ¸ | ďźďźďźďźďźďźďźďźďźďźďźďźďźäşć°čŻĺšśďźťď˝ďź˝ďźťďźďźďźďź˝äşć°§éç°ćçŻďźďźďźĺşďźç°ä¸çˇç˛éŻčşĺşďźďźďźďźç˛ĺşĺĄĺśďźďźďźĺşďźčŻç˛é ¸äšĺşéŤĺ˝˘ĺź |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | ĐĐľŃŃĐľĐşŃ Đ¤Đ°ŃПаŃŃŃŃикаНС ĐнкОŃпОŃоКŃод | ХпОŃОй пОНŃŃĐľĐ˝Đ¸Ń ŃикНОаНкиНкаŃйОкŃаПидО-индОНŃĐ˝ŃŃ ŃОодинониК |
| KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | ěě¤ěźě´ë°ě´ě¤í 죟ěíěŹ | ě 경 ě¸íŹ ěŹëЏ ëë ě 경 í´í뼟 ěľě í기 ěí ě˝íě 쥰ěąëŹź |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | ăăźăăăŻăš ăăĄăźăăˇăĽăźăăŁăŤăŤăş ă¤ăłăłăźăăŹă¤ăăă | ďźď˝ďźâďźâďźďźďźďźâă¸ăăŤăŞăăăłăžďźťď˝ďź˝ďźťďźďźďźďź˝ă¸ăŞăă˝ăźăŤâďźâă¤ăŤďźâď˝âďźďźâďźďźďźďźâă¸ăăăăăˇăăăăŤďźâďźâăăŤăŞăâďźâďźďźâăăăăăˇâďźâăĄăăŤăăăăłâďźâă¤ăŤďźâďźď˝âă¤ăłăăźăŤâďźâă¤ăŤďźăˇăŻăăăăăłăŤăŤăăăľăăăĺŤăĺťčŹçľćçŠăăăłăăŽćä¸ |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP2717855A4 (en) | 2011-06-07 | 2014-11-12 | Parion Sciences Inc | Methods of Treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e åcidos nucleicos modificados e respetivas utilizaçþes |
| CA2852991C (en) | 2011-11-08 | 2019-12-31 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| KR101452235B1 (ko) * | 2012-02-03 | 2014-10-22 | ěě¸ëíęľě°ííë Ľë¨ | ě ęˇí íźëŚŹëŻ¸ëęł ě ë체 ëë ě´ě ě˝íě ěźëĄ íěŠę°ëĽí ěź, ě´ě ě ěĄ°ë°Šë˛ ë° ě´ëĽź íŹí¨íë ď˝ď˝ď˝ď˝ ěěŠě˛´ ę´ë ¨ ě§íě ěë°Š ëë ěšëŁěŠ ě˝íě 쥰ěąëŹź |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | ç°äťŁć˛ťçĺ Źĺ¸ | ç¨äşäş§çä¸äşşçąťçžç ç¸ĺ łçççŠĺśĺĺčç˝č´¨ç俎鼰ĺ¤ć ¸čˇé ¸ |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| WO2013181232A2 (en) | 2012-05-29 | 2013-12-05 | Michael Ross Johnson | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| KR102396897B1 (ko) | 2012-11-02 | 2022-05-13 | ë˛í ě¤ íë§ěí°ěšźě¤ ě¸ě˝íŹë ě´í°ë | ď˝ď˝ď˝ 매ę°ë ě§íě ěšëŁëĽź ěí ě˝ě íě 쥰ěąëŹź |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porçþes terminais |
| US8987461B2 (en) | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| RU2671976C2 (ru) | 2012-12-17 | 2018-11-08 | ĐŃŃиОн ХаКонŃиС, Đнк. | ĐĄĐžĐľĐ´Đ¸Đ˝ĐľĐ˝Đ¸Ń 3,5-диаПинО-6-Ń ĐťĐžŃ-n-(n-(4-ŃониНйŃŃиН)каŃйаПиПидОиН)пиŃаСин-2-каŃйОкŃаПида |
| ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | KlĂłrpirazin-karboxamid-szĂĄrmazĂŠkok nem kielĂŠgĂtĂľ nyĂĄlkahĂĄrtya-hidratĂĄciĂł ĂĄltal elĂľsegĂtett megbetegedĂŠsek kezelĂŠsĂŠre |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| WO2014163934A1 (en) * | 2013-03-13 | 2014-10-09 | Dow Agrosciences Llc | Preparation of 1,3-(substituted-diaryl)-1,2,4-triazoles |
| CA2903103C (en) * | 2013-03-15 | 2020-06-09 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| HK1218537A1 (zh) | 2013-03-15 | 2017-02-24 | Discoverybiomed Inc. | éŚčąç´ čĄççŠäťĽĺç¨ćźć˛ťçčżĺşŚĺ˘çć§çžç çćšćł |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| ES2657989T3 (es) * | 2013-03-15 | 2018-03-07 | Monsanto Technology Llc | Azoles n-, c-disustituidos para controlar plagas de nematodos |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모ëë ě¸ëźí¨íąě¤, ě¸ě˝íŹë ě´í°ë | ě ë°ë ě§ë¨ë°ąě§ ěěŠě˛´ëĽź ěí¸ííë í´ëŚŹë´í´ë ě¤íě´ë |
| FR3011468B1 (fr) * | 2013-10-04 | 2015-12-04 | Inventiva | Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose |
| WO2015054283A1 (en) * | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | ë˛í ě¤ íë§ěí°ěšźě¤ ě¸ě˝íŹë ě´í°ë | Dna-pk ěľě ě ëĄě (s)-n-ëŠí¸-8-(1-((2'-ëŠí¸-[4,5'-ëšíźëŚŹëŻ¸ë]-6-ěź)ěëŻ¸ë ¸)íëĄí-2-ěź)í´ë댰-4-ěš´ëłľě¤ě미ë ë° ě´ě ëí ëĄíë ě ë체ě 곾결ě |
| WO2015134711A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| PL3925607T5 (pl) | 2014-04-15 | 2026-06-01 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorĂłb, w ktĂłrych poĹredniczy mukowiscydozowy przezbĹonowy regulator przewodnictwa |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | çžĺçśćł°ĺ ćŻčŁ˝čĽĺ Źĺ¸ | ĺč Ťçşçśĺç表čĺłĺ°čŞżçŻčç˝äščŞżçŻĺ |
| HK1245246A1 (zh) | 2014-12-01 | 2018-08-24 | ćçżźççŠĺťčŻç§ć(ä¸ćľˇ)ćéĺ Źĺ¸ | ä˝ä¸şćş´ĺćĺśĺçĺ䝣ĺĄĺśé Ž |
| CN107207488B (zh) * | 2014-12-17 | 2020-11-17 | 䟌ćŚç厜ĺŚé˘ | ä˝ä¸şč§éťé ¸ĺä˝Î˛(RARβ)ćżĺ¨ĺçĺçŻćčłĺş-ćčłĺş-čŻç˛é ¸ĺĺçŠ |
| US10647688B2 (en) * | 2014-12-19 | 2020-05-12 | Galderma Research & Development | Compounds, synthesis method thereof and use of same in medicine and in cosmetics |
| WO2016105491A1 (en) | 2014-12-23 | 2016-06-30 | Fgh Biotech | Compositions of fatostatin based heterocyclic compounds and uses thereof |
| ES2895729T3 (es) * | 2015-07-24 | 2022-02-22 | Syngenta Participations Ag | Derivados de 1,2,4-triazol activos como plaguicidas con sustituyentes con contenido en azufre |
| TW201729807A (zh) | 2015-10-30 | 2017-09-01 | ďź°ď˝ď˝ć˛ťçĺ Źĺ¸ | ç¨ćźć˛ťçç˛ççćšćł |
| WO2017108569A1 (en) | 2015-12-22 | 2017-06-29 | Syngenta Participations Ag | Pesticidally active pyrazole derivatives |
| CA3048202A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by inhibition of nonsense mediated decay |
| US11497738B2 (en) | 2016-04-29 | 2022-11-15 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
| WO2017205503A1 (en) | 2016-05-24 | 2017-11-30 | Indiana University Research And Technology Corporation | Ku inhibitors and their use |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| EP3510027B1 (en) | 2016-09-07 | 2022-11-02 | FGH BioTech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que daĂąan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| KR102599339B1 (ko) * | 2016-12-20 | 2023-11-08 | ë¸ëŚŹě¤í¨-ë§ě´ě´ě¤ ě¤í ěť´íźë | 늴ě쥰ě ě ëĄě ě ěŠí ííŠëŹź |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapĂŠuticas para el tratamiento de las enfermedades hepĂĄticas |
| WO2018187479A1 (en) * | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
| CN110831593A (zh) * | 2017-06-14 | 2020-02-21 | çšçť´ĺ¨ćéĺ Źĺ¸ | ç¨äşč°čs1p1ć´ťć§çĺĺçŠĺĺ śä˝żç¨ćšćł |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| JP2020525434A (ja) | 2017-06-22 | 2020-08-27 | ă ăźăłăˇă§ăă ăăĄăźă ă¨ăŤă¨ăŤăˇăź | ă˘ăłăŹăăľăăŻăšĺăłĺ çŤčŞżçŻĺ¤ăĺŤăçľćçŠă§çă沝çăăćšćł |
| WO2019040724A1 (en) * | 2017-08-23 | 2019-02-28 | The Regents Of The University Of Michigan | SMALL MYC INHIBITOR MOLECULES AND USES THEREOF |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | MĂŠtodos de elaboraciĂłn de nanopartĂculas lipĂdicas. |
| WO2019101709A1 (en) | 2017-11-23 | 2019-05-31 | Universita' Degli Studi Di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
| WO2019124577A1 (ko) * | 2017-12-20 | 2019-06-27 | ěŹë¨ë˛ě¸ 경기ë경ě ęłźíě§íĽě | í¸ëŚŹě쥸 ě ë체 ë° ě´ě ěŠë |
| WO2019185736A1 (de) * | 2018-03-29 | 2019-10-03 | Explo Engineering Ag | Vorrichtung und verfahren zur erzeugung von druckwellen hoher amplitude |
| GB201806004D0 (en) | 2018-04-11 | 2018-05-23 | Karin & Sten Mortstedt Cbd Solutions Ab | Selective ligands for TAU aggregates |
| WO2019209777A1 (en) * | 2018-04-23 | 2019-10-31 | The Curators Of The University Of Missouri | Improved crispr therapy |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길댏ě ë ěŹě´ě¸ěěŚ, ě¸ě˝íŹë ě´í°ë | Fxr (nr1h4) 쥰ě ííŠëŹź |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | ćŠçťçşłçšćŻćéĺ Źĺ¸ | ĺśĺ¤č质纳繳é˘ç˛çćšćł |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| US11299487B2 (en) * | 2019-03-26 | 2022-04-12 | Neuropore Therapies, Inc. | Compounds and compositions as modulators of TLR signaling |
| US20230000982A1 (en) * | 2019-09-25 | 2023-01-05 | Korea Institute Of Radiological & Medical Sciences | Composition for preventing or treating cancer, containing novel trifluoromethyl phenyl pyrazole derivative as active ingredient |
| KR102663365B1 (ko) * | 2019-09-25 | 2024-05-08 | íęľěěë Ľěíě | ě ęˇ í¸ëŚŹí루ě¤ëĄëŠí¸íëíźëźěĄ¸ ě ë체뼟 ě í¨ěąëśěźëĄ í¨ě íë ě ěë°Š ëë ěšëŁěŠ ěĄ°ěąëŹź |
| MX2022005766A (es) | 2019-11-19 | 2022-08-08 | Trevena Inc | Compuestos y mĂŠtodos para la preparaciĂłn de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1). |
| WO2021119242A1 (en) * | 2019-12-10 | 2021-06-17 | The Trustees Of Indiana University | Replication protein a (rpa)-dna interaction inhibitors |
| KR102847693B1 (ko) * | 2019-12-27 | 2025-08-18 | ěě¸ëíęľě°ííë Ľë¨ | ěĽěŹëě쥸 ě ë체뼟 íŹí¨íë ëšë§ě ěë°Š ëë ěšëŁěŠ ěĄ°ěąëŹź |
| EP3912628A1 (en) | 2020-05-20 | 2021-11-24 | Institut de Recherche en Semiochimie et Ethologie AppliquĂŠe | Nucleoside analogues to inhibit the main protease of a coronavirus |
| WO2022168962A1 (ja) * | 2021-02-04 | 2022-08-11 | ĺ˝çŤĺ¤§ĺŚćłäşşäšĺˇĺ¤§ĺŚ | ď˝ďźďźďźçŁçćĺśĺ¤ăĺăłăăăĺŤćăăĺťčŹçľćçŠ |
| CN115594642B (zh) * | 2021-06-28 | 2024-12-27 | 嚿輿ĺťç§ĺ¤§ĺŚ | éżé˝çć źä¸ć°ŽĺčĄççŠĺĺ śćäšłč şçç¨é |
| EP4173485A1 (en) * | 2021-10-27 | 2023-05-03 | Max-Planck-Gesellschaft zur FĂśrderung der Wissenschaften e.V. | Protein aggregation inhibiting compounds for plant disease control |
| KR20230140410A (ko) * | 2022-03-25 | 2023-10-06 | ë°ě¤í ëź ěŁźěíěŹ | 3-íëě´ěěŹěĄ¸ ě ë체 ë° ě´ëĽź ě í¨ěąëśěźëĄ í¨ě íë ěě§í ěë°Š ëë ěšëŁěŠ ě˝í 쥰ěąëŹź |
| JP2025540931A (ja) | 2022-11-03 | 2025-12-17 | ăťăłăăăăŻăš ă¤ăłăłăźăăŹă¤ăăă | ăżăŚĺéä˝ăŤĺŻžăăé¸ćçăŞăŹăłă |
| GB202300021D0 (en) * | 2023-01-03 | 2023-02-15 | Thirtyfivebio Ltd | Compounds |
| WO2025116596A1 (ko) * | 2023-11-29 | 2025-06-05 | ę°ě˛ëíęľ ě°ííë Ľë¨ | ě ęˇ ííŠëŹź ë° ě´ëĽź íŹí¨íë ěě§í ěë°Š ëë ěšëŁěŠ ěĄ°ěąëŹź |
| CN120987868A (zh) * | 2024-08-08 | 2025-11-21 | ĺčŻçşŞĺ (桹ĺł)ĺťčŻćéĺ Źĺ¸ | ä¸ç§äşĺ ĺšśĺ ĺ ćçŻĺĺçŠĺĺ śĺśĺ¤ćšćłĺĺşç¨ |
| CN119144004B (zh) * | 2024-08-12 | 2025-10-28 | ĺ °ĺˇĺ¤§ĺŚ | ä¸ç§m-hofććĺĺ śĺśĺ¤ćšćłĺĺ¨ć°˘ć°§ć šçŚťĺčŻĺŤä¸çĺşç¨ |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3153017A (en) * | 1961-06-29 | 1964-10-13 | Eastman Kodak Co | Nitrogen-containing linear polyesters from amino methyl cyclohexanol and dicarboxylic acids |
| CH489510A (de) | 1967-02-07 | 1970-04-30 | Geigy Ag J R | Verfahren zur Herstellung von substituierten v-Triazolen |
| GB1263940A (en) | 1968-08-02 | 1972-02-16 | Innothera Lab Sa | 0-phenyl-pyrroles |
| GB1248070A (en) * | 1968-12-16 | 1971-09-29 | Science Union & Cie | Thiazolyl-benzoic acid derivatives and process for preparing them |
| US3803162A (en) | 1969-10-03 | 1974-04-09 | Sandoz Ltd | 7-triazolyl-3-phenylcoumarins |
| US3679669A (en) | 1970-09-23 | 1972-07-25 | Ciba Geigy Ag | Phenyl-1,3,4-oxdiazole compounds |
| US3882138A (en) * | 1971-08-09 | 1975-05-06 | Uniroyal Inc | Oxazole and oxadiazole benzoic acid derivatives as herbicides |
| US3964896A (en) * | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
| BE789948A (fr) | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
| US3948937A (en) | 1972-02-29 | 1976-04-06 | E. I. Du Pont De Nemours And Company | Pyrazole plant growth regulants |
| US4035175A (en) | 1974-07-29 | 1977-07-12 | Uniroyal Inc. | Method of retarding the growth of plants using certain oxadiazolyl, oxazolyl or thiadiazolyl benzoic acid derivatives |
| US3947263A (en) | 1974-07-29 | 1976-03-30 | Uniroyal, Inc. | Plant growth regulants |
| AU497898B2 (en) | 1975-01-10 | 1979-01-18 | Commonwealth Scientific And Industrial Research Organisation | Plant growth regulating method and composition for use therein |
| US4038285A (en) * | 1975-06-25 | 1977-07-26 | E. I. Du Pont De Nemours And Company | 1-(2-carboxyaryl)-4-arylimidazoles and 1-(2-carboxyaryl)-3-aryl-1,2,4-triazoles |
| US4032644A (en) | 1975-12-29 | 1977-06-28 | Sandoz, Inc. | Isoxazolyl benzoic acids |
| DE2722331A1 (de) | 1976-05-18 | 1977-11-24 | Ricoh Kk | 1,3,4-oxadiazolderivate sowie diese enthaltende elektrophotographische aufzeichnungsmaterialien |
| US4140515A (en) * | 1977-05-12 | 1979-02-20 | Monsanto Company | Aryl-3-isoxazole benzoates as plant growth regulants and herbicides |
| US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
| US4268299A (en) * | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
| US4210762A (en) * | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| CA1125768A (en) * | 1978-10-31 | 1982-06-15 | Hoffmann-La Roche Limited | Benzoxazole derivatives |
| US4229204A (en) | 1978-12-04 | 1980-10-21 | Monsanto Company | Trifluoromethylphenyl isoxazolyl benzoates |
| JPS58177977A (ja) | 1982-04-09 | 1983-10-18 | Grelan Pharmaceut Co Ltd | ďźâăă¨ăăŤăăŠăžâăŤéĄ |
| SU1063100A1 (ru) * | 1982-04-22 | 1985-06-30 | ĐŃодпŃиŃŃио Đ/ĐŻ Đ-7850 | ĐидкОкŃиŃŃаННиŃĐľŃкиК ПаŃĐľŃиаН Đ´Đť ŃНокŃŃООпŃиŃĐľŃĐşĐ¸Ń ŃŃŃŃОКŃŃв |
| US4760066A (en) * | 1982-09-21 | 1988-07-26 | Wayne State University | Method for treating human tumor cell metastasis |
| US4546113A (en) * | 1983-04-14 | 1985-10-08 | Pfizer Inc. | Antiprotozoal diamidines |
| DD226883A1 (de) * | 1984-07-30 | 1985-09-04 | Neubauer T Paedagog Hochschule | Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen |
| US5436252A (en) * | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| DE3819037A1 (de) * | 1988-06-04 | 1989-12-14 | Hoechst Ag | 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden |
| US5260451A (en) * | 1989-05-11 | 1993-11-09 | Merckle Gmbh | Substituted pyrrole compounds and use thereof in pharmaceutical compositions |
| US5022915A (en) * | 1990-03-01 | 1991-06-11 | Ici Americas Inc. | Substituted 2,4-diarylpyrimidines and their use as herbicides |
| CA2073981C (en) | 1990-11-30 | 2002-01-08 | Shiro Kondo | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| FR2672050A1 (fr) | 1991-01-30 | 1992-07-31 | Atochem | Diaryl-2,5 oxadiazoles-1,3,4 hydroxyester, hydroxyacide et acetoxyacide, leur procede de synthese. |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| IL112290A (en) * | 1994-01-12 | 1999-01-26 | Novartis Ag | Transformed aryl and the troiryl pyrimidines and herbicides containing them |
| US5521189A (en) | 1994-05-06 | 1996-05-28 | The University Of Nc At Ch | Methods of treating pneumocystis carinii pneumonia |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| WO1996011210A1 (en) * | 1994-10-07 | 1996-04-18 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic hexapeptides having antibiotic activity |
| US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| JP3964478B2 (ja) * | 1995-06-30 | 2007-08-22 | ă¨ăźăśă¤ăťă˘ăźăŤăťă˘ăłăăťăăŁăźăťăăă¸ăĄăłăć Şĺźäźç¤ž | ăăăç°ĺŤćăŤăŤăăłé ¸čŞĺ°ä˝ĺăłăăăĺŤćăăĺťčŹ |
| DE19536811A1 (de) * | 1995-10-02 | 1997-04-03 | Basf Ag | Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel |
| KR100485642B1 (ko) | 1996-03-18 | 2005-09-30 | ěěě´ ę°ëśěí¤ę°ě´ě¤ | ěśíŠęł 댏í¨ě 운뼴볾ě¤ě°ě ë체 |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| MY128323A (en) | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
| WO1998015532A1 (en) * | 1996-10-09 | 1998-04-16 | Novartis Ag | Solid phase synthesis of heterocyclic compounds |
| KR20000069128A (ko) * | 1996-11-25 | 2000-11-25 | ë°ě´ëšë ě 모ě´ě´ | ěí-2 ěëë ë 댰ěěŠě˛´ ěęł ëě¤í¸ëĄě ě ěŠí 2-ě´ëݏë¤ěĄ¸ëŚŹëěëŻ¸ë ¸ë˛¤ěŚěĽěŹěĄ¸ ííŠëŹź |
| WO1998028421A1 (en) | 1996-12-20 | 1998-07-02 | Human Genome Sciences, Inc. | Human oncogene induced secreted protein i |
| SI1023063T1 (en) * | 1997-10-06 | 2004-02-29 | Abbott Gmbh & Co. Kg | INDENO(1,2-c), NAPHTHO(1,2-c)- AND BENZO(6,7)CYCLOHEPTA(1,2-c)PYRAZOLE DERIVATIVES |
| DE69818083T2 (de) * | 1997-10-06 | 2004-07-08 | Abbott Gmbh & Co. Kg | INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE |
| IT1300055B1 (it) | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| WO1999040108A1 (en) * | 1998-02-09 | 1999-08-12 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| AU4005299A (en) * | 1998-05-19 | 1999-12-06 | Regents Of The University Of California, The | Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis |
| ATE315033T1 (de) * | 1998-08-07 | 2006-02-15 | Chiron Corp | Subtituierte isoxazole derivate als estrogen rezeptor modulatore |
| DE19904389A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
| DE19904406A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Substituierte Pyrazolcarbonsäuren |
| DE60022386T2 (de) * | 1999-12-16 | 2006-06-22 | Schering Corp. | Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten |
| US7729756B2 (en) | 2000-01-18 | 2010-06-01 | Siemens Aktiengesellschaft | Measurement system for examining a section of tissue on a patient and the use of a measurement system of this type |
| IL150987A0 (en) | 2000-02-11 | 2003-02-12 | Genentech Inc | Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
| AU2001245401A1 (en) * | 2000-03-01 | 2001-09-12 | Sumitomo Pharmaceuticals Company, Limited | Hydrazones and analogs as cholesterol lowering agents |
| DZ3347A1 (fr) * | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | DĂŠrivĂŠs d'arylmĂŠthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| GB0012362D0 (en) | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| WO2002036580A2 (en) * | 2000-10-31 | 2002-05-10 | Lynn Bonham | Benzoxazole lpaat- beta inhibitors and uses thereof |
| PL369598A1 (en) * | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| CA2446387A1 (en) | 2001-05-09 | 2002-11-14 | Sumitomo Chemical Takeda Agro Company, Limited | Azole compound, process for producing the same and use thereof |
| JP2003026663A (ja) | 2001-05-09 | 2003-01-29 | Takeda Chem Ind Ltd | ă˘ăžăźăŤĺĺçŠăăăŽčŁ˝é ćłăăăłç¨é |
| EP1405636A4 (en) * | 2001-06-26 | 2009-04-15 | Takeda Pharmaceutical | FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR |
| JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | ăŹăăă¤ăé˘éŁĺ厚ä˝ćŠč˝čŞżçŻĺ¤ |
| DE10136066A1 (de) * | 2001-07-25 | 2003-02-13 | Bayer Cropscience Ag | Tetrahydropyridazin-Derivate |
| US20070010562A1 (en) * | 2001-08-13 | 2007-01-11 | Ulrike Bauer | Nr1h4 nuclear receptor binding compounds |
| AU2002340010A1 (en) * | 2001-09-26 | 2003-04-07 | Bayer Corporation | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| EP1458708B1 (en) * | 2001-12-18 | 2007-09-26 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | ăĄăŤăŻ ă¨ăłă ăŤă ăăăź ă¤ăłăłăźăăŹăźăăă | ăĄăżăăăăăăŻă°ăŤăżăăłé ¸ĺ厚ä˝âďźăŽăăăă˘ăŞăźăŤç˝ŽćăăŠăžăźăŤçłťčŞżçŻĺ¤ |
| JP4357965B2 (ja) | 2001-12-21 | 2009-11-04 | ăĄăŤăŻ ă¨ăłă ăŤă ăăăź ă¤ăłăłăźăăŹăźăăă | ăĄăżăăăăăăŻă°ăŤăżăăłé ¸ĺ厚ä˝âďźăŽăăăă˘ăŞăźăŤç˝ŽćăăăźăŤă˘ă¸ăĽăŹăźăżăź |
| US7229987B2 (en) * | 2002-05-13 | 2007-06-12 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| AU2003234567A1 (en) * | 2002-05-15 | 2003-12-02 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
| WO2004009610A2 (en) * | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases |
| EP1525185A1 (en) * | 2002-07-24 | 2005-04-27 | PTC Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| EP1542667B1 (en) * | 2002-07-24 | 2012-03-07 | PTC Therapeutics, Inc. | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| CA2495285A1 (en) * | 2002-08-13 | 2004-02-19 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for gaba receptors |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| JP2006501263A (ja) * | 2002-09-09 | 2006-01-12 | ă˘ă ă¸ă¨ăłăťă¤ăłăłăźăăŹăźăăă | çç沝çç¨ăŽďź´ďźŽďźŚâÎąăăăłă¤ăłăżăźăă¤ăăłä˝ä¸ĺ¤ă¨ăăŚăŽďźďźďźďźďźâ罎ćďźďźďźâă¸ăăăâăăŠăžăźăŤâďźâăŞăłăăăłďźâă˘ăŤăłăăˇâďźďź¨âăăŠăžăźăŤčŞĺ°ä˝ |
| AU2003283597A1 (en) * | 2002-11-16 | 2004-06-15 | Oxford Glycosciences (Uk) Ltd | Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors |
| US20040176264A1 (en) * | 2002-12-30 | 2004-09-09 | The Procter & Gamble Company | Rinse aid composition containing water-soluble metal salt for use in automatic dishwashing for glassware corrosion protection |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| ES2325440T3 (es) * | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
| US7320986B2 (en) * | 2003-03-07 | 2008-01-22 | Abbott Labortories | Fused tri and tetra-cyclic pyrazole kinase inhibitors |
| EP4101846B1 (en) | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US7226930B2 (en) | 2003-04-18 | 2007-06-05 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors |
| EP1784400B1 (en) | 2004-08-23 | 2015-01-14 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| JP2008515992A (ja) * | 2004-10-13 | 2008-05-15 | ăăźăăŁăźăˇăź ăťăŠăăĽăźăăŁăŻăšďźă¤ăłăłăźăăŹăźăăă | ä˝ç´°čĺ¤ç°ăŤčľˇĺ ăăçžćŁăŽéťć˘ďźć˛ťçç¨ĺťčŹă製é ăăăăăŽčŚĺŽĺĺçŠăŽä˝żç¨ |
| WO2007059356A2 (en) * | 2005-11-19 | 2007-05-24 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1 |
| EP2284154A1 (en) * | 2009-07-29 | 2011-02-16 | Argon Pharma S.L. | Antitumor 1,2-diphenylpyrrole compounds and their preparation process |
-
2005
- 2005-10-13 JP JP2007536867A patent/JP2008515992A/ja active Pending
- 2005-10-13 WO PCT/US2005/036761 patent/WO2006044502A2/en not_active Ceased
- 2005-10-13 EP EP10185133A patent/EP2363129A1/en not_active Withdrawn
- 2005-10-13 JP JP2007536837A patent/JP2008515985A/ja active Pending
- 2005-10-13 WO PCT/US2005/036764 patent/WO2006044505A2/en not_active Ceased
- 2005-10-13 KR KR1020077010794A patent/KR20070065429A/ko not_active Withdrawn
- 2005-10-13 MX MX2007004479A patent/MX2007004479A/es unknown
- 2005-10-13 US US11/577,177 patent/US9051342B2/en not_active Expired - Fee Related
- 2005-10-13 CA CA002582885A patent/CA2582885A1/en not_active Abandoned
- 2005-10-13 JP JP2007536865A patent/JP2008515990A/ja active Pending
- 2005-10-13 EP EP10185130.1A patent/EP2311455B1/en not_active Expired - Lifetime
- 2005-10-13 US US11/577,192 patent/US7902235B2/en not_active Expired - Fee Related
- 2005-10-13 US US11/577,189 patent/US9315467B2/en active Active
- 2005-10-13 CA CA002583177A patent/CA2583177A1/en not_active Abandoned
- 2005-10-13 EP EP05804171A patent/EP1812071A2/en not_active Withdrawn
- 2005-10-13 WO PCT/US2005/037052 patent/WO2006044682A1/en not_active Ceased
- 2005-10-13 KR KR1020077009154A patent/KR20070067165A/ko not_active Withdrawn
- 2005-10-13 AU AU2005295730A patent/AU2005295730A1/en not_active Abandoned
- 2005-10-13 SG SG200906828-9A patent/SG156640A1/en unknown
- 2005-10-13 BR BRPI0515995-4A patent/BRPI0515995A/pt not_active IP Right Cessation
- 2005-10-13 MX MX2007004487A patent/MX2007004487A/es unknown
- 2005-10-13 EP EP10185126.9A patent/EP2301538B1/en not_active Expired - Lifetime
- 2005-10-13 CA CA002583976A patent/CA2583976A1/en not_active Abandoned
- 2005-10-13 EP EP05804194A patent/EP1799207A2/en not_active Withdrawn
- 2005-10-13 US US11/577,191 patent/US9611230B2/en not_active Expired - Fee Related
- 2005-10-13 BR BRPI0516110-0A patent/BRPI0516110A/pt not_active IP Right Cessation
- 2005-10-13 CA CA002583971A patent/CA2583971A1/en not_active Abandoned
- 2005-10-13 EP EP05807667A patent/EP1799659A1/en not_active Withdrawn
- 2005-10-13 WO PCT/US2005/036673 patent/WO2006044456A1/en not_active Ceased
- 2005-10-13 WO PCT/US2005/036762 patent/WO2006044503A2/en not_active Ceased
- 2005-10-13 US US11/577,176 patent/US20080269191A1/en not_active Abandoned
- 2005-10-13 EP EP05815159.8A patent/EP1815206B1/en not_active Expired - Lifetime
- 2005-10-13 EP EP05807462A patent/EP1799212A2/en not_active Withdrawn
- 2005-10-13 EP EP10185128.5A patent/EP2301536B1/en not_active Expired - Lifetime
- 2005-10-13 EP EP10185137A patent/EP2316452A1/en not_active Withdrawn
- 2005-10-13 EP EP10185139A patent/EP2402323A3/en not_active Withdrawn
- 2005-10-13 EP EP16163831.7A patent/EP3067053A1/en not_active Withdrawn
- 2005-10-13 CA CA002583159A patent/CA2583159A1/en not_active Abandoned
- 2005-10-13 EP EP15168072.5A patent/EP2939674A1/en not_active Withdrawn
- 2005-10-13 AU AU2005295778A patent/AU2005295778A1/en not_active Abandoned
- 2005-10-13 MX MX2007004484A patent/MX2007004484A/es unknown
- 2005-10-13 KR KR1020077010767A patent/KR20070067201A/ko not_active Withdrawn
- 2005-10-13 AU AU2005295727A patent/AU2005295727A1/en not_active Abandoned
- 2005-10-13 SG SG200906829-7A patent/SG156641A1/en unknown
-
2007
- 2007-04-11 IL IL182459A patent/IL182459A0/en unknown
- 2007-04-11 IL IL182464A patent/IL182464A0/en unknown
- 2007-04-11 IL IL182461A patent/IL182461A0/en unknown
-
2011
- 2011-03-07 US US13/042,456 patent/US8710031B2/en not_active Expired - Fee Related
-
2014
- 2014-04-28 US US14/263,478 patent/US9273076B2/en not_active Expired - Lifetime
-
2015
- 2015-06-08 US US14/733,615 patent/US20150274674A1/en not_active Abandoned
-
2016
- 2016-04-15 US US15/130,318 patent/US20160229818A1/en not_active Abandoned
-
2017
- 2017-03-31 US US15/475,240 patent/US20170204073A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL182464A0 (en) | Compounds for nonsense suppression, and methods for their use | |
| IL207967A0 (en) | Methods, compositions, and apparatuses for forming macrocyclic compounds | |
| ZA200700351B (en) | Compounds, compositions and methods | |
| IL186599A0 (en) | Methods for treating and preventing fibrosis | |
| IL183278A0 (en) | Rod-coupling assemblies | |
| GB0616111D0 (en) | Agents, methods and uses | |
| PL1811990T3 (pl) | Ĺrodki przeciw demodekozie | |
| TWI367222B (en) | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof | |
| GB0403629D0 (en) | Methods | |
| GB0423552D0 (en) | Methods | |
| HK1110771A (en) | Compounds for nonsense suppression, and methods for their use | |
| HK1107842A (en) | Compounds for nonsense suppression, and methods for their use | |
| ZA200702933B (en) | Compounds for nonsense suppression and methods for their use | |
| GB0415805D0 (en) | Chair | |
| GB0408156D0 (en) | Process and compounds | |
| GB2414745C (en) | Euroblock - flood prevention specification | |
| GB0400310D0 (en) | Anti-incrustation agent | |
| GB0415757D0 (en) | Methods | |
| GB0409752D0 (en) | New security features | |
| EP1712219A4 (en) | AGENT DECREASING WRINKLES | |
| PL368096A1 (en) | Wetting-washing agent | |
| AU157093S (en) | Tunic | |
| AU156684S (en) | Tunic | |
| AU157089S (en) | Tunic | |
| AU156686S (en) | Tunic |